Answer
Sirolimus inhibits T-cell activation by blocking intracellular signalling; experimental evidence suggests it binds the protein FKPB-12 to form a complex that inhibits mTOR, a kinase critical for cell-cycle progression, thereby inhibiting lymphocyte activation.
Sources for this answer
- Rapamune 2 mg coated tabletsPfizer Limited · emc · SmPC §5.1 Pharmacodynamic properties · Version 54Document updated
Sources checked